CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 512 enrolled
Drug / intervention
Lasmiditan +1 moredrug
Likely dose
Lasmiditan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00883051
NCT00883051Phase 2Completed
CompareCT.gov

A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine

Eli Lilly and Company·interventional·Posted Apr 17, 2009·Updated Dec 23, 2019

In Brief

A Phase 2 clinical trial evaluating Lasmiditan and Placebo for Migraine Disorders. Completed, enrolled 512 participants across 39 sites in 5 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesBelgium, Finland, France, Germany, Spain
CollaboratorsCoLucid Pharmaceuticals

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 17, 2009
Enrollment StartJul 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.2 years ago

Interventions

Lasmiditandrug

Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.

Placebodrug

Placebo